Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
1993
Size (employees)
42 (est)
Biocept was founded in 1993 and is headquartered in San Diego, US

Key People at Biocept

Michael W. Wallace

Michael W. Wallace

President & CEO
Lyle Arnold

Lyle Arnold

SVP & CSO

Biocept Office Locations

Biocept has an office in San Diego
San Diego, US (HQ)
5810 Nancy Ridge Dr

Biocept Data and Metrics

Biocept Financial Metrics

Biocept's revenue was reported to be $1.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.7 m

Gross profit (Q1, 2017)

(446.4 k)

Gross profit margin (Q1, 2017), %

(27%)

EBIT (Q1, 2017)

(4.4 m)

Market capitalization (18-Aug-2017)

32.1 m

Cash (31-Dec-2016)

4.6 m
Biocept's current market capitalization is $32.1 m.
USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(16.9 m)(18.4 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

76.8 k164.9 k221.4 k662.9 k1 m1.7 m

Cost of goods sold

985.2 k1.2 m1.5 m1.7 m1.9 m2.1 m

Gross profit

(908.5 k)(994.9 k)(1.3 m)(1 m)(829 k)(446.4 k)

Gross profit Margin, %

(1183%)(603%)(566%)(152%)(79%)(27%)

Sales and marketing expense

851.1 k1.1 m1.3 m1.3 m1.3 m1.3 m

R&D expense

772.1 k677.7 k728.1 k716.3 k600.6 k757.3 k

General and administrative expense

1.4 m1.6 m1.5 m1.5 m1.9 m1.9 m

Operating expense total

3 m3.4 m3.5 m3.5 m3.8 m3.9 m

EBIT

(3.9 m)(4.4 m)(4.8 m)(4.5 m)(4.6 m)(4.4 m)

EBIT margin, %

(5068%)(2644%)(2156%)(684%)(442%)(261%)

Interest expense

(169 k)(176.1 k)(138.4 k)(99.7 k)(154.9 k)(82.5 k)

Pre tax profit

(4 m)(4.5 m)(4.9 m)(4.6 m)(4.7 m)(4.4 m)

Income tax expense

(355)(199)(1.6 k)(503)(199)(1.6 k)
USDFY, 2014FY, 2015FY, 2016

Cash

5.4 m8.8 m4.6 m

Accounts Receivable

10.6 k34.2 k129 k

Inventories

338.7 k435.9 k484.6 k

Current Assets

5.9 m9.6 m5.8 m

Total Assets

6.6 m10.6 m7.6 m

Accounts Payable

641.4 k632.5 k960.5 k

Current Liabilities

1.4 m3.3 m4.4 m

Total Liabilities

6.9 m

Additional Paid-in Capital

138.1 m158.9 m174.3 m

Retained Earnings

(138.3 m)(155.2 m)(173.6 m)

Total Equity

658.7 k

Financial Leverage

11.5 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(15.9 m)(16.9 m)(18.4 m)

Depreciation and Amortization

251.2 k261.4 k322 k

Accounts Receivable

(1.4 k)(23.6 k)(94.8 k)

Inventories

(401.4 k)(80.4 k)494.7 k

Accounts Payable

(981.9 k)(51.8 k)332.7 k

Cash From Operating Activities

(14.6 m)(15.2 m)(15.7 m)

Cash From Investing Activities

(394.9 k)(165.2 k)(451.4 k)

Cash From Financing Activities

20.3 m18.8 m11.9 m

Interest Paid

402.1 k405.7 k358.6 k

Income Taxes Paid

8002.2 k2.1 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Accounts Receivable

15.6 k32.1 k40.4 k43.4 k86.7 k85.7 k834.9 k

Accounts Payable

970.5 k612.5 k766.4 k853.3 k946.3 k1.7 m1.4 m
USDY, 2017

Revenue/Employee

40.1 k

Biocept Market Value History

Traffic Overview of Biocept

Biocept Online and Social Media Presence

Biocept Company Life and Culture

You may also be interested in